Compounds > au1235
Page last updated: 2024-11-13

au1235

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID54752297
CHEMBL ID1818385
SCHEMBL ID18464994
SCHEMBL ID18464996
SCHEMBL ID18423981
MeSH IDM0573800

Synonyms (14)

Synonym
CHEMBL1818385 ,
bdbm50351247
1-(1-adamantyl)-3-(2,3,4-trifluorophenyl)urea
1338780-86-1
AKOS029865185
au1235
SCHEMBL18464994
SCHEMBL18464996
HY-101867
CS-6863
SCHEMBL18423981
au-1235;au 1235
BCP34030
MS-24826

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" However, these compounds suffered from poor in vitro pharmacokinetic (PK) profiles and they have a similar structure/SAR to inhibitors of human soluble epoxide hydrolase (sEH) enzymes."( Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties.
Bruhn, DF; Grzegorzewicz, A; Hess, T; Jackson, M; Jones, V; Lee, RE; Maddox, MM; McNeil, MR; Morisseau, C; North, EJ; Scarborough, JS; Scherman, MS; Yang, L, 2013)		0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bifunctional epoxide hydrolase 2Homo sapiens (human)IC50 (µMol)0.00400.00000.54509.1000AID1601280; AID1722863; AID1814168; AID613884
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
response to toxic substanceBifunctional epoxide hydrolase 2Homo sapiens (human)
positive regulation of gene expressionBifunctional epoxide hydrolase 2Homo sapiens (human)
dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
cholesterol homeostasisBifunctional epoxide hydrolase 2Homo sapiens (human)
stilbene catabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
phospholipid dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
regulation of cholesterol metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
magnesium ion bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide hydrolase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
toxic substance bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
10-hydroxy-9-(phosphonooxy)octadecanoate phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lipid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
protein homodimerization activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lysophosphatidic acid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomal matrixBifunctional epoxide hydrolase 2Homo sapiens (human)
cytosolBifunctional epoxide hydrolase 2Homo sapiens (human)
extracellular exosomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID751983Solubility of the compound in system solution buffer at pH 7.4 after 18 hrs by UV spectrometry analysis2013Bioorganic & medicinal chemistry, May-01, Volume: 21, Issue:9
Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties.
AID613893Antibacterial activity against Klebsiella pneumoniae2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID1601285Apparent permeability across basolateral to apical membrane in human Caco2 cells at 10 uM measured after 2 hrs by UPLC-MS/MS analysis2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.
AID1722863Inhibition of recombinant human soluble epoxide hydrolase using CMNPC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors:
AID613881Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID1601283Solubility of compound in 1% DMSO : 99% PBS buffer solution at 37 degree C measured after 2 hrs by nephelometer analysis2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.
AID613888Antibacterial activity against Bacillus anthracis2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID613892Antibacterial activity against Pseudomonas aeruginosa2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID613880Antituberculosis activity against Mycobacterium tuberculosis H37Rv after 7 days by microbroth dilution method2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID1722865Apparent permeability across apical to basolateral side in human Caco-2 cells at 10 uM measured after 2 hrs by LC-MS/MS analysis2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors:
AID1288656Antimycobacterial activity against Mycobacterium tuberculosis H37Rv
AID1601282Microsomal stability in human microsomes assessed as parent compound remaining in presence of NADP, glucose-6-phosphate and glucose-6-phosphate dehydrogenase measured after 60 mins by UPLC-MS/MS analysis2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.
AID613887Antibacterial activity against Enterococcus faecalis2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID613886Antibacterial activity against Enterococcus faecium2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID1814169Metabolic stability in human liver recombinant microsomes assessed as parent compound remaining measured after 60 mins in presence of NADP by UPLC-MS/MS analysis2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
From the Design to the
AID613884Inhibition of human recombinant soluble epoxide hydrolase using CMNPC as substrate after 10 mins by fluorescent assay2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID613895Selectivity index, ratio of IC50 for african green monkey Vero cells to MIC for Mycobacterium tuberculosis H37Rv2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID613890Antibacterial activity against Escherichia coli expressing TolC2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID1601286Efflux ratio of apparent permeability across basolateral to apical membrane over apical to basolateral membrane in human Caco2 cells at 10 uM measured after 2 hrs by UPLC-MS/MS analysis2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.
AID1601280Inhibition of recombinant human liver soluble epoxide hydrolase expressed in baculovirus infected Sf21 cells using NEPC as substrate by fluorescence based assay2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.
AID613883Inhibition of Mycobacterium tuberculosis recombinant EphE expressed in Escherichia coli BL21 using CMNPC as substrate at 10 nM after 30 mins by fluorescent assay relative to control2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID1601284Apparent permeability across apical to basolateral membrane in human Caco2 cells at 10 uM measured after 2 hrs by UPLC-MS/MS analysis2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.
AID1722866Apparent permeability across basolateral to apical side in human Caco-2 cells at 10 uM measured after 2 hrs by LC-MS/MS analysis2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors:
AID1814171Metabolic stability in rat liver recombinant microsomes assessed as parent compound remaining measured after 60 mins in presence of NADP by UPLC-MS/MS analysis2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
From the Design to the
AID613894Antituberculosis activity against Mycobacterium smegmatis MC2 155 after 7 days by microbroth dilution method2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID613882Inhibition of Mycobacterium tuberculosis recombinant EphB expressed in Escherichia coli BL21 using CMNPC as substrate at 10 nM after 30 mins by fluorescent assay relative to control2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID1814170Metabolic stability in mouse liver recombinant microsomes assessed as parent compound remaining measured after 60 mins in presence of NADP by UPLC-MS/MS analysis2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
From the Design to the
AID1722864Solubility of the compound in 1% DMSO/99% PBS buffer solution measured after 2 hrs by light scattering based assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors:
AID1814168Inhibition of human recombinant sEH using CMNPC as substrate incubated for 5 mins by fluorescent based assay2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
From the Design to the
AID1722867Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Caco-2 cells at 10 uM measured after 2 hrs by LC-MS/MS analysis2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors:
AID1601281Inhibition of murine soluble epoxide hydrolase expressed in baculovirus infected Sf21 cells using NEPC as substrate by fluorescence based assay2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.
AID613891Antibacterial activity against Escherichia coli K122011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (60.00)24.3611
2020's2 (40.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.28 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		2.0610carbohydrazideantitubercular agent;
drug allergen
triclocarban
triclocarban: bacteriostat; antiseptic in soaps & other cleansing solns; germicide; structure. triclocarban : A member of the class of phenylureas that is urea substituted by a 4-chlorophenyl group and a 3,4-dichlorophenyl group at positions 1 and 3 respectively.		2.0610dichlorobenzene;
monochlorobenzenes;
phenylureas		antimicrobial agent;
antiseptic drug;
disinfectant;
environmental contaminant;
xenobiotic
1,3-diphenylurea
1,3-diphenylurea : A member of the class of phenylureas that is urea in which one of the hydrogens of each amino group is replaced by a phenyl group. It is present in coconut milk (Cocos nucifera).		2.0610phenylureascytokinin;
plant metabolite
ethambutol
Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.		2.0610ethanolamines;
ethylenediamine derivative		antitubercular agent;
environmental contaminant;
xenobiotic
thiocarlide
thiocarlide: major descriptor (68-85); on-line search PHENYLTHIOUREA/AA (68-85); Index Medicus search THIOCARLIDE (68-85); Antitubercular Agent		2.0610thioureas
ar 9281
[no description available]		2.9430
4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid
[no description available]		2.9430
ConditionIndicatedRelationship StrengthStudiesTrials
Koch's Disease
[description not available]		02.0810
Tuberculosis
Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.		02.0810
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Acute Edematous Pancreatitis
[description not available]		02.6920
Acute Disease
Disease having a short and relatively severe course.		02.6920
Pancreatitis
INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.		02.6920